Liaoning Chengda Biotechnology Co.,Ltd.
- Country
- Ownership
- -
- Established
- 2002-06-17
- Employees
- 1.7K
- Market Cap
- -
- Website
- https://www.cdbio.cn
- Introduction
The company was founded in June 2002. With the corporate mission of “providing high-quality biological products and caring for human life and health”, the company always adheres to the core values of “honesty, kindness and harmony, and responsibility and cooperation”, adheres to the corporate philosophy of “facing life, only responsibility”, and is committed to becoming an excellent international biopharmaceutical company. The company's main business is R&D, production and sales of human vaccines. The main products are human rabies vaccine and human encephalitis B vaccine. Corporate glory: high-tech enterprise, Liaoning Science and Technology Award, independent innovation of famous products, etc.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
5
Drug Approvals
Japanese Encephalitis Vaccine (Vero cell), Inactivated ,Freeze-dried
- Product Name
- 冻干乙型脑炎灭活疫苗(Vero细胞)
- Approval Number
- 国药准字S20083042
- Approval Date
- Dec 27, 2022
Japanese Encephalitis Vaccine (Vero cell),Inactivated
- Product Name
- 乙型脑炎灭活疫苗(Vero细胞)
- Approval Number
- 国药准字S20083041
- Approval Date
- Dec 27, 2022
Japanese Encephalitis Vaccine(Vero Cell), Inactivated
- Product Name
- 乙型脑炎灭活疫苗(Vero细胞)
- Approval Number
- 国药准字S20202001
- Approval Date
- Dec 27, 2022
Rabies Vaccine (Vero cell) for Human Use, Freeze-dried
- Product Name
- 冻干人用狂犬病疫苗(Vero细胞)
- Approval Number
- 国药准字S20043090
- Approval Date
- Jun 24, 2020
Rabies Vaccine (Vero Cell) for Human Use
- Product Name
- 人用狂犬病疫苗(Vero细胞)
- Approval Number
- 国药准字S20043089
- Approval Date
- Jun 24, 2020